This site is intended for health professionals only

Teva Launches TevaGrastim (filgrastim)

teaser

Teva UK Limited has signalled its commitment to developing biosimilar medicines by entering the G-CSF therapy area.

The launch of its proprietary version of filgrastim, TevaGrastim, marks the Company’s first biosimilar, and represents a major addition to Teva’s Hospitals portfolio.

TevaGrastim is licenced for a number of indications, the most common being the reduction of chemotherapy-induced neutropenia. The product is available in two presentations, both are available from wholesalers, ie, 30 MIU pre-filled syringe (5 pack) and 48 MIU pre-filled syringe (5 pack).

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

TevaGrastim is licensed for the same indications as the reference product, Neupogen (filgrastim). Teva’s pre-filled syringe will also incorporate a needle guard to minimise the risk of needle stick injuries.

When comparing NHS list prices of filgrastim products, TevaGrastim is a competitively priced G-CSF treatment.

Teva






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x